Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +34.35%
#2 Siren Siren +31.73%
#3 OriginTrail OriginTrail +18.20%
#4 Purr Purr +17.28%
#5 龙虾 (Lobster) 龙虾 (Lobster) +12.28%
#6 Ethena Staked ENA Ethena Staked ENA +11.62%
#7 Wrapped XPL Wrapped XPL +11.23%
#8 DigiByte DigiByte +11.00%
#9 Collect on Fanable Collect on Fanable +10.98%
#10 Plasma Plasma +10.85%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

PRTK
Classifica tra le azioni #21736
Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in... Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.
Prezzo delle azioni
$2.23
Ultima sincronizzazione: 2023-09-29
Capitalizzazione di mercato
$101.43M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Paratek Pharmaceuticals, Inc. (PRTK)

Categoria

Healthcare
Il prezzo PRTK con la capitalizzazione del mercato della B
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
PRTK
$2.23
Capitalizzazione di mercato di Paratek Pharmaceuticals, Inc.(PRTK)
Capitalizzazione di mercato: $101.43M
A partire dal August 2026, Paratek Pharmaceuticals, Inc. ha una capitalizzazione di mercato pari a $101.43M. Questo rende Paratek Pharmaceuticals, Inc. la 21736th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Paratek Pharmaceuticals, Inc. dal 2009 al 2026
PRTK in paragone con la classifica dei più popolari stocks
Il prezzo per PRTK Attivo B Capitalizzazione del mercato a B Risultati
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$114,578 $101.43M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +5,137,926.54%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$99,965.49 $101.43M
Apple Inc. Apple Inc.
AAPL
$4.547T +4,482,657.23%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$91,516.86 $101.43M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +4,103,795.24%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$78,991.67 $101.43M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,542,127.48%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$61,404.14 $101.43M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,753,449.00%